Sign in
CompletedNo phase

Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients

Key facts

Who runs it
University of Minnesota
Where
Minneapolis, United StatesSee the site
Trial code
Status
Completed
People taking part
74 people enrolled
Started
11 Sept 2023
Ended
16 Jun 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Fluzone High-Dose - 2 doses
  • Fluzone High-Dose - 1 dose of HD
Record updated
15 July 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • >=18 years old who underwent a solid organ transplant (Liver, lung, heart, kidney, pancreas) > 1 year prior to enrollment
  • At least 1-year post-transplant
  • Able and willing to provide informed consent
  • Able and willing to undergo all study activities throughout the duration of the study

Who cannot take part

  • History of a severe allergy to influenza vaccine (i.e. Guillain Barre syndrome, anaphylaxis or angioedema)
  • Confirmed pregnancy
  • Receipt of ATG or carfilzomib within the past 3 months
  • Receipt of rituximab within the past 3 months
  • Receipt of basiliximab within the past 3 months
  • Prednisone dose >= 20 mg/day at the time of enrollment

Where in United States

  • University of MinnesotaMinneapolis, United States

About the trial

What the trial wants to find out

In solid organ transplant (SOT) the receipt of influenza vaccine in an influenza season is associated with decreased disease severity as demonstrated by the presence of pneumonia and ICU admissions. Different strategies have been assessed to optimize vaccine efficacy and immunogenicity of the influenza vaccine in the solid organ transplant recipient (SOTR). The primary objective of the study is to evaluate the immunogenicity of 2 doses of the high dose influenza vaccine utilizing neutralizing antibody assays. A control group receiving 1 HD influenza vaccine will be included.

The 2 groups in the trial

  • booster groupTreatment being tested

    Participants who have undergone a solid organ transplant will receive two doses of an inactivated high dose influenza vaccine

    Treatment: Fluzone High-Dose - 2 doses

  • Control groupExisting treatment, for comparison

    Participants who have undergone a solid organ transplant will receive one dose of inactivated high dose influenza vaccine followed by a placebo injection

    Treatment: Fluzone High-Dose - 1 dose of HD

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
15 July 2025